We demonstrate that an antibody that selectively detects a validated CDK5 phosphorylation site on the substrate CRMP2 robustly stains NSCLC, B-cell lymphoma and to a lesser extent breast carcinoma. Here, DPYSL2 is linked to B-cell non-Hodgkin lymphoma.